Cardiovascular effects of acute treatment with the antipsychotic drug olanzapine in rats

Vascular Pharmacology

Volumn 62, Issue 3, 2014, Pages 143-149

  Leung, Joanne Y T ^a   Pang, Catherine C Y ^a   Procyshyn, Ric M ^b   Barr, Alasdair M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b British Columbia Mental Health and Addictions Research Institute   (Canada)

Author keywords

Antipsychotic drugs; Cardiovascular; Hypotension; Olanzapine; Venous tone

Indexed keywords

OLANZAPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; HEART MUSCLE CONTRACTILITY; HEART RATE; IN VIVO STUDY; INDWELLING CATHETER; MALE; MEAN ARTERIAL PRESSURE; MEAN CIRCULATORY FILLING PRESSURE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SYSTOLIC BLOOD PRESSURE; VEIN TONE; VENOUS RETURN; ANIMAL; ARTERIAL PRESSURE; BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECTS; HEART CONTRACTION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; ARTERIAL PRESSURE; BENZODIAZEPINES; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; MALE; MYOCARDIAL CONTRACTION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 85027954793     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2014.06.003     Document Type: Article

References (62)

1. Bresee L.C., Majumdar S.R., Patten S.B., Johnson J.A. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res 2010, 117:75-82.
2. Laursen T.M., Munk-Olsen T., Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 2012, 25:83-88.
3. Leung J.Y., Barr A.M., Procyshyn R.M., Honer W.G., Pang C.C. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther 2012, 135:113-122.
4. Muench J., Hamer A.M. Adverse effects of antipsychotic medications. Am Fam Physician 2010, 81:617-622.
5. Ray W.A., Chung C.P., Murray K.T., Hall K., Stein C.M. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009, 360:225-235.
6. Vieweg W.V., Wood M.A., Fernandez A., Beatty-Brooks M., Hasnain M., Pandurangi A.K. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 2009, 26.
7. Procyshyn R.M., Honer W.G., Wu T.K., Ko R.W., McIsaac S.A., Young A.H., et al. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 2010, 71:566-573.
8. Procyshyn R.M., Su J., Elbe D., Liu A.Y., Panenka W.J., Davidson J., et al. Prevalence and patterns of antipsychotic use in youth at the time of admission and discharge from an inpatient psychiatric facility. J Clin Psychopharmacol 2014, 34:17-22.
9. Drici M.D., Wang W.X., Liu X.K., Woosley R.L., Flockhart D.A. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol 1998, 18:477-481.
10. Studenik C., Lemmens-Gruber R., Heistracher P. Proarrhythmic effects of antidepressants and neuroleptic drugs on isolated, spontaneously beating guinea-pig Purkinje fibers. Eur J Pharm Sci 1999, 7:113-118.
11. Hennessy S., Bilker W.B., Knauss J.S., Margolis D.J., Kimmel S.E., Reynolds R.F., et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ 2002, 325:1070.
12. Aygit A.C., Ayhan M.S., Demiralay A., Yildirim I. Vascular effects of epinephrine, lisinopril, and chlorpromazine in diabetic and non-diabetic rats. J Reconstr Microsurg 1999, 15:439-441.
13. Ipsen M., Zhang Y., Dragsted N., Han C., Mulvany M.J. The antipsychotic drug sertindole is a specific inhibitor of alpha1a-adrenoceptors in rat mesenteric small arteries. Eur J Pharmacol 1997, 336:29-35.
14. Nourian Z., Mow T., Muftic D., Burek S., Pedersen M.L., Matz J., et al. Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function. Psychopharmacology (Berl) 2008, 199:15-27.
15. Markowitz J.S., Brown C.S., Moore T.R. Atypical antipsychotics. Part I: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999, 33:73-85.
16. De Hert M., Detraux J., van Winkel R., Yu W., Correll C.U. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011, 8:114-126.
17. Boyda H.N., Procyshyn R.M., Tse L., Hawkes E., Jin C.H., Pang C.C., et al. Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. J Psychiatry Neurosci 2012, 37:407-415.
18. Boyda H.N., Tse L., Procyshyn R.M., Honer W.G., Barr A.M. Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci 2010, 31:484-497.
19. Boyda H.N., Procyshyn R.M., Pang C.C., Hawkes E., Wong D., Jin C.H., et al. Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine. PLoS One 2013, 8:e53459.
20. Boyda H.N., Procyshyn R.M., Tse L., Xu J., Jin C.H., Wong D., et al. Antipsychotic polypharmacy increases metabolic dysregulation in female rats. Exp Clin Psychopharmacol 2013, 21:164-171.
21. Boyda H.N., Procyshyn R.M., Asiri Y., Wu C., Wang C.K., Lo R., et al. Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2014, 48:170-176.
22. Bymaster F.P., Nelson D.L., DeLapp N.W., Falcone J.F., Eckols K., Truex L.L., et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res 1999, 37:107-122.
23. Pang C.C. Measurement of body venous tone. J Pharmacol Toxicol Methods 2000, 44:341-360.
24. Yamamoto J., Trippodo N.C., Ishise S., Frohlich E.D. Total vascular pressure-volume relationship in the conscious rat. Am J Physiol 1980, 238:H823-H828.
25. Boyda H.N., Tse L., Procyshyn R.M., Wong D., Wu T.K., Pang C.C., et al. A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:945-954.
26. Barr A.M., Procyshyn R.M., Hui P., Johnson J.L., Honer W.G. Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. Schizophr Res 2008, 100:252-260.
27. Baitz H.A., Thornton A.E., Procyshyn R.M., Smith G.N., MacEwan G.W., Kopala L.C., et al. Antipsychotic medications: linking receptor antagonism to neuropsychological functioning in first episode psychosis. J Int Neuropsychol Soc 2012, 18:717-727.
28. Vera P.L., Miranda-Sousa A., Nadelhaft I. Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats. BMC Pharmacol 2001, 4.
29. Markowitz J.S., DeVane C.L., Malcolm R.J., Gefroh H.A., Wang J.S., Zhu H.J., et al. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacol 2006, 46:164-171.
30. Markowitz J.S., DeVane C.L., Boulton D.W., Liston H.L., Risch S.C. Hypotension and bradycardia in a healthy volunteer following a single 5mg dose of olanzapine. J Clin Pharmacol 2002, 42:104-106.
31. Pretorius J.L., Phillips M., Langley R.W., Szabadi E., Bradshaw C.M. Comparison of clozapine and haloperidol on some autonomic and psychomotor functions, and on serum prolactin concentration, in healthy subjects. Br J Clin Pharmacol 2001, 52:322-326.
32. Tandon R. Safety and tolerability: how do newer generation "atypical" antipsychotics compare?. Psychiatr Q 2002, 73:297-311.
33. Chandrasena R., Dvorakova D., Lee S.I., Loza N., Mosolov S.N., Osvath P., et al. Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania. Int J Clin Pract 2009, 63:1249-1258.
34. Nwazue V.C., Raj S.R. Confounders of vasovagal syncope: orthostatic hypotension. Cardiol Clin 2013, 31:89-100.
35. Thomas G.D. Neural control of the circulation. Adv Physiol Educ 2011, 35:28-32.
36. Nedergaard O.A., Abrahamsen J. Effect of chlorpromazine on sympathetic neuroeffector transmission in the rabbit isolated pulmonary artery and aorta. Br J Pharmacol 1988, 93:23-34.
37. Gugger J.J. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS Drugs 2011, 25:659-671.
38. Perez-Rivera A.A., Fink G.D., Galligan J.J. Increased reactivity of murine mesenteric veins to adrenergic agonists: functional evidence supporting increased alpha1-adrenoceptor reserve in veins compared with arteries. J Pharmacol Exp Ther 2004, 308:350-357.
39. D'Oyley H.M., Pang C.C. Effects of alpha 1- and alpha 2-adrenoceptor antagonists on venous tone in conscious rats. Eur J Pharmacol 1990, 182:283-290.
40. Brosda J., Jantschak F., Pertz H.H. Alpha2-adrenoceptors are targets for antipsychotic drugs. Psychopharmacology (Berl) 2014, 231:801-812.
41. Pang C.C., Tabrizchi R. The effects of noradrenaline, B-HT 920, methoxamine, angiotensin II and vasopressin on mean circulatory filling pressure in conscious rats. Br J Pharmacol 1986, 89:389-394.
42. Villamil-Hernandez M.T., Alcantara-Vazquez O., Sanchez-Lopez A., Manrique-Maldonado G., Villalon C.M., Centurion D. Pharmacological identification of the alpha(2)-adrenoceptor subtypes mediating the vasopressor responses to B-HT 933 in pithed rats. Eur J Pharmacol 2012, 691:118-124.
43. Gavin K.T., Colgan M.P., Moore D., Shanik G., Docherty J.R. Alpha 2C-adrenoceptors mediate contractile responses to noradrenaline in the human saphenous vein. Naunyn Schmiedebergs Arch Pharmacol 1997, 355:406-411.
44. Beasley C.M., Sanger T., Satterlee W., Tollefson G., Tran P., Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996, 124:159-167.
45. Rasnayake L.R., Wimalarathne H., Jayapala R.K., Gamage C.D., Dassanayake D.L., Ratnayake S.L., et al. An unusual case of hypothermia associated with therapeutic doses of olanzapine: a case report. J Med Case Rep 2011, 5:189.
46. Palenzona S., Meier P.J., Kupferschmidt H., Rauber-Luethy C. The clinical picture of olanzapine poisoning with special reference to fluctuating mental status. J Toxicol Clin Toxicol 2004, 42:27-32.
47. Singh L.K., Praharaj S.K., Sahu M. Nonfatal suicidal overdose of olanzapine in an adolescent. Curr Drug Saf 2012, 7:328-329.
48. Morgan M., Hackett L.P., Isbister G.K. Olanzapine overdose: a series of analytically confirmed cases. Int Clin Psychopharmacol 2007, 22:183-186.
49. O'Brien P., Oyebode F. Psychotropic medication and the heart. Adv Psychiatr Treat 2003, 9:414-423.
50. Guo L., Dong Z., Guthrie H. Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates. J Pharmacol Toxicol Methods 2009, 60:130-151.
51. Malpas S.C. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev 2010, 90:513-557.
52. Vanoli E., Bacchini S., Panigada S., Pentimalli F., Adamson P.B. Experimental models of heart failure. Eur Heart J 2004, F7-F15.
53. Poluzzi E., Raschi E., Koci A., Moretti U., Spina E., Behr E.R., et al. Antipsychotics and torsadogenic risk: signals emerging from the US FDA adverse event reporting system database. Drug Saf 2013, 36:467-479.
54. Kluge M., Schuld A., Himmerich H., Dalal M., Schacht A., Wehmeier P.M., et al. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol 2007, 27:662-666.
55. Ellingrod V.L., Schultz S.K., Ekstam-Smith K., Kutscher E., Turvey C., Arndt S. Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. Pharmacotherapy 2002, 22:1-5.
56. Baptista T., Serrano A., Uzcategui E., ElFakih Y., Rangel N., Carrizo E., et al. The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela. Schizophr Res 2011, 126:93-102.
57. Reaven G.M., Lieberman J.A., Sethuraman G., Kraemer H., Davis J.M., Blasey C., et al. In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. J Psychiatr Res 2009, 43:997-1002.
58. Chen V.C., Wang T.N., Lu M.L., Chou J.Y., Ju P.C., Wu J.Y., et al. Weight gain and ghrelin level after olanzapine monotherapy. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:632-635.
59. Cheon Y., Park J.Y., Modi H.R., Kim H.W., Lee H.J., Chang L., et al. Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin e(2) concentration in rat brain. J Neurochem 2011, 119:364-376.
60. Patil B.M., Kulkarni N.M., Unger B.S. Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain. Eur J Pharmacol 2006, 551:112-115.
61. Boyda H.N., Procyshyn R.M., Tse L., Wong D., Pang C.C., Honer W.G., et al. Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. Neuropharmacology 2012, 62:1391-1400.
62. Boyda H.N., Ramos-Miguel A., Procyshyn R.M., Topfer E., Lant N., Choy H.H., et al. Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats. Int J Neuropsychopharmacol 2014, 17:77-90.